Adagen

Severe Combined Immunodeficiency, Autosomal Recessive, T Cell-Negative, B Cell-Negative, NK Cell-Negative, Due To Adenosine Deaminase Deficiency

Leadiant Biosciences, Inc.UNKNOWNPhase 3Dormant

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

1 Active assets in the Severe Combined Immunodeficiency, Autosomal Recessive, T Cell-Negative, B Cell-Negative, NK Cell-Negative, Due To Adenosine Deaminase Deficiency cohort.

Asset / Sponsor	Phase	Rating
Elapegademase Leadiant Biosciences, Inc.	Phase 3	BB
Peg-Ada Great Ormond Street Hospital for Children NHS Foundation Trust	Phase 1/2	CCC
Busulfanum Great Ormond Street Hospital for Children NHS Foundation Trust	Phase 1/2	CCC
Infusion Of Autologous Efs-Ada Lv Cd34+ Cells Great Ormond Street Hospital for Children NHS Foundation Trust	Phase 1/2	CCC
Cyclosporin A Fred Hutchinson Cancer Center	Phase 1	CC
Simoladagene Autotemcel Lentiviral Vector University of California, Los Angeles	Unknown	D

Same molecule, other indications

Adagen is also rated in:

severe combined immunodeficiencyDormant

Indicative · Phase 3

64 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →